XENON PHARMACEUTICALS INC. Variable Lease, Cost
XENON PHARMACEUTICALS INC. (XENE) reported Variable Lease, Cost of $218.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-06
- XENON PHARMACEUTICALS INC. variable lease, cost for the quarter ending 2026-06-30 was $218.00K, a 5.31% increase year-over-year.
- XENON PHARMACEUTICALS INC. variable lease, cost for the quarter ending 2026-03-31 was $219.00K, a 9.50% increase year-over-year.
- XENON PHARMACEUTICALS INC. variable lease, cost for the quarter ending 2025-12-31 was $214.00K, a 3.38% increase year-over-year.
- XENON PHARMACEUTICALS INC. variable lease, cost for the quarter ending 2025-09-30 was $210.00K, a 1.94% increase year-over-year.
- XENON PHARMACEUTICALS INC. variable lease, cost for fiscal 2025 was $831.00K, a 0.61% increase from fiscal 2024.
- XENON PHARMACEUTICALS INC. variable lease, cost for fiscal 2024 was $826.00K, a 4.96% increase from fiscal 2023.
- XENON PHARMACEUTICALS INC. variable lease, cost for fiscal 2023 was $787.00K, a 1.68% increase from fiscal 2022.
- XENON PHARMACEUTICALS INC. variable lease, cost for fiscal 2022 was $774.00K, a 3.06% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 3 month as first filed | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $218.00K 10-Q · filed 2026-08-06 | $437.00K 10-Q · filed 2026-08-06 | $651.00K derived: sum of 3 quarters · filed 2026-08-06 | $861.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $219.00K 10-Q · filed 2026-05-07 | $433.00K derived: sum of 2 quarters · filed 2026-05-07 | $643.00K derived: sum of 3 quarters · filed 2026-05-07 | $850.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $214.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $424.00K derived: sum of 2 quarters · filed 2026-02-26 | $631.00K derived: sum of 3 quarters · filed 2026-08-06 | $831.00K 10-K · filed 2026-02-26 | |
| 2025-09-30 | $210.00K 10-Q · filed 2025-11-03 | $417.00K derived: sum of 2 quarters · filed 2026-08-06 | $617.00K 10-Q · filed 2025-11-03 | $824.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $207.00K 10-Q · filed 2026-08-06 | $407.00K 10-Q · filed 2026-08-06 | $614.00K derived: sum of 3 quarters · filed 2026-08-06 | $820.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $200.00K 10-Q · filed 2026-05-07 | $407.00K derived: sum of 2 quarters · filed 2026-05-07 | $613.00K derived: sum of 3 quarters · filed 2026-05-07 | $818.00K derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $207.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $413.00K derived: sum of 2 quarters · filed 2026-02-26 | $618.00K derived: sum of 3 quarters · filed 2026-02-26 | $826.00K 10-K · filed 2026-02-26 | |
| 2024-09-30 | $206.00K 10-Q · filed 2025-11-03 | $411.00K derived: sum of 2 quarters · filed 2025-11-03 | $619.00K 10-Q · filed 2025-11-03 | $813.00K derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $205.00K 10-Q · filed 2025-08-11 | $413.00K 10-Q · filed 2025-08-11 | $607.00K derived: sum of 3 quarters · filed 2026-02-26 | $805.00K derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $208.00K 10-Q · filed 2025-05-12 | $402.00K derived: sum of 2 quarters · filed 2026-02-26 | $600.00K derived: sum of 3 quarters · filed 2026-02-26 | $798.00K derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $392.00K derived: sum of 2 quarters · filed 2026-02-26 | $590.00K derived: sum of 3 quarters · filed 2026-02-26 | $787.00K 10-K · filed 2026-02-26 | |
| 2023-09-30 | $198.00K 10-Q · filed 2024-11-12 | $396.00K derived: sum of 2 quarters · filed 2024-11-12 | $593.00K 10-Q · filed 2024-11-12 | $789.00K derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $198.00K 10-Q · filed 2024-08-08 | $395.00K 10-Q · filed 2024-08-08 | $591.00K derived: sum of 3 quarters · filed 2025-02-27 | $786.00K derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $197.00K 10-Q · filed 2024-05-09 | $393.00K derived: sum of 2 quarters · filed 2025-02-27 | $588.00K derived: sum of 3 quarters · filed 2025-02-27 | $779.00K derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $196.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $391.00K derived: sum of 2 quarters · filed 2025-02-27 | $582.00K derived: sum of 3 quarters · filed 2025-02-27 | $774.00K 10-K · filed 2025-02-27 | |
| 2022-09-30 | $195.00K 10-Q · filed 2023-11-08 | $386.00K derived: sum of 2 quarters · filed 2023-11-08 | $578.00K 10-Q · filed 2023-11-08 | $770.00K derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-06-30 | $191.00K 10-Q · filed 2023-08-09 | $383.00K 10-Q · filed 2023-08-09 | $575.00K derived: sum of 3 quarters · filed 2024-02-29 | $760.00K derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-03-31 | $192.00K 10-Q · filed 2023-05-09 | $384.00K derived: sum of 2 quarters · filed 2024-02-29 | $569.00K derived: sum of 3 quarters · filed 2024-02-29 | $759.00K derived: sum of 4 quarters · filed 2024-02-29 | |
| 2021-12-31 | $192.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $377.00K derived: sum of 2 quarters · filed 2024-02-29 | $567.00K derived: sum of 3 quarters · filed 2024-02-29 | $751.00K 10-K · filed 2024-02-29 | |
| 2021-09-30 | $185.00K 10-Q · filed 2022-11-08 | $375.00K derived: sum of 2 quarters · filed 2022-11-08 | $559.00K 10-Q · filed 2022-11-08 | $704.00K derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | $190.00K 10-Q · filed 2022-08-09 | $374.00K 10-Q · filed 2022-08-09 | $519.00K derived: sum of 3 quarters · filed 2023-03-01 | $656.00K derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | $184.00K 10-Q · filed 2022-05-10 | $329.00K derived: sum of 2 quarters · filed 2023-03-01 | $466.00K derived: sum of 3 quarters · filed 2023-03-01 | $598.00K derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-12-31 | $145.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $282.00K derived: sum of 2 quarters · filed 2023-03-01 | $414.00K derived: sum of 3 quarters · filed 2023-03-01 | $549.00K 10-K · filed 2023-03-01 | |
| 2020-09-30 | $137.00K 10-Q · filed 2021-11-10 | $269.00K derived: sum of 2 quarters · filed 2021-11-10 | $404.00K 10-Q · filed 2021-11-10 | $543.00K derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $132.00K 10-Q · filed 2021-08-11 | $267.00K 10-Q · filed 2021-08-11 | $406.00K derived: sum of 3 quarters · filed 2021-08-11 | $542.00K derived: sum of 4 quarters · filed 2021-08-11 | |
| 2020-03-31 | $136.00K 10-Q · filed 2021-05-11 | $274.00K derived: sum of 2 quarters · filed 2021-05-11 | $410.00K derived: sum of 3 quarters · filed 2021-05-11 | $544.00K derived: sum of 4 quarters · filed 2021-05-11 | |
| 2019-12-31 | $138.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $274.00K derived: sum of 2 quarters · filed 2021-03-01 | $408.00K derived: sum of 3 quarters · filed 2021-03-01 | $542.00K 10-K · filed 2021-03-01 | |
| 2019-09-30 | $136.00K 10-Q · filed 2020-11-05 | $270.00K derived: sum of 2 quarters · filed 2020-11-05 | $404.00K 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $134.00K 10-Q · filed 2020-08-06 | $268.00K 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $135.00K 10-Q/A · filed 2020-05-26 | $179.00K 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |